Dennis Phillip Andrew sold $6K of NBP
Dennis Phillip Andrew (Chief Medical Officer) sold 8,209 shares of NovaBridge Biosciences (NBP) at $0.71 on 2026-09-18.
How this was made
The 30-second read
Why it matters
The disclosed sale is modest and unlikely to influence market perception of NovaBridge Biosciences.
Market read
Routine insider sale with minimal market impact.
What to watch
Potential upcoming dilution or secondary offering could contextualize insider sales.
Background
SEC Form 4 filing discloses insider transactions for public companies.
Ticker impact
Chief Medical Officer Dennis Phillip Andrew sold 8,209 shares of NovaBridge Biosciences for $5,828.39 on Sep 18, 2026.
Minimal impact; likely negligible price movement.
The transaction size is small relative to total float and does not indicate a change in insider confidence.
Market effects
None; the sale does not affect the biotech sector broadly.
None; limited to NovaBridge Biosciences shareholders.
None
Counterpoint
The sale could be interpreted as a lack of confidence, but size is too small to be meaningful.
Key entities
- CompanyNovaBridge Biosciences
Biotech firm listed under ticker NBP.
- IndividualDennis Phillip Andrew
Chief Medical Officer of NovaBridge Biosciences.